OC 50 - Novel hemophilia treatment, clinical trials II

Moderator(s)

• 

  Omolade Awodu, MD FMCPath

  Professor and Consultant Haematologist
  University of Benin Teaching Hospital, Benin City, Nigeria
  Benin City, Nigeria
• 

  Saskia Prasca, MEDICAL DOCTOR

  Hematologist and hemophilia specialist
  Medicarte, Antioquia, Colombia

Presentations:

• 09:30 – 09:45 ICT

  First interim analysis of clinical outcomes in adults and adolescents with severe hemophilia A receiving efanesoctocog alfa prophylaxis in XTEND-ed, a phase 3 long-term extension study
  

  Presenting Author: Sophie Susen, PhD,MD – Centre Hospitalier Universitaire de Lille, Université de Lille, Lille, France

  Co-Author: Stephanie P'ng – The Haemophilia and Haemostasis Centre, Fiona Stanley Hospital, Murdoch, Australia

  Co-Author: Toshko Lissitchkov – Specialized Hospital for Active Treatment of Hematological Diseases, Department of Chemotherapy, Hemotherapy and Hereditary Blood Diseases at Clinical Hematology Clinic, Sofia, Bulgaria

  Co-Author: Davide Matino – Division of Hematology & Thromboembolism, Department of Medicine, McMaster University, Ontario, Canada

  Co-Author: Pratima Chowdary, MD – Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital

  Co-Author: Angela Weyand, MD – Division of Hematology/Oncology, Department of Pediatrics, University of Michigan Medical School, Ann Arbor, MI, USA

  Co-Author: Robert Klamroth, MD – Vivantes Klinikum, Friedrichshain, Berlin, Germany

  Co-Author: Young-Shil Park – Department of Pediatrics, Kyung Hee University Hospital at Gangdong, School of Medicine, Kyung Hee University, Seoul, Korea

  Co-Author: María Teresa Alvarez-Román, MD, PhD – Department of Hematology, University Hospital La Paz, Autonoma University of Madrid, Madrid, Spain

  Co-Author: Liqi Feng – Sanofi, Shanghai, China

  Co-Author: Helena Palmborg – Sobi, Stockholm, Sweden

  Co-Author: Jennifer Dumont – Sanofi, Cambridge, MA, USA

  Co-Author: Elena Santagostino – Sobi, Basel, Switzerland

  Co-Author: Lila-Sabrina Fetita – Sanofi, Paris, France

  Co-Author: Keiji Nogami – Nara Medical University, Nara, Japan
• 09:45 – 10:00 ICT

  Long-term outcomes with efanesoctocog alfa prophylaxis for previously treated children with severe hemophilia A, an interim analysis of the phase 3 XTEND-ed study
  

  Co-Author: Lynn Malec – Versiti Blood Research Institute, Milwaukee, WI, USA

  Co-Author: Beatrice Nolan – Children's Health Ireland at Crumlin, Dublin, Republic of Ireland

  Co-Author: Anthony KC Chan, MBBS – McMaster Children’s Hospital, McMaster University, Hamilton, Canada

  Presenting Author: Manuela Albisetti – University Children's Hospital Zurich, Zurich, Switzerland

  Co-Author: Sheng-Chieh Chou, MD. – Department of Internal Medicine, National Taiwan University Hospital

  Co-Author: Bulent Zulfikar – Department of Pediatric Hematology, Istanbul University Oncology Institute, Inherited Bleeding Disorders Center, Istanbul, Turkey

  Co-Author: Mindy Simpson – Rush Hemophilia and Thrombophilia Center, Rush University Medical Center, Chicago, IL, USA

  Co-Author: Liqi Feng – Sanofi, Shanghai, China

  Co-Author: Helena Palmborg – Sobi, Stockholm, Sweden

  Co-Author: Graham Neill – Sanofi, Reading, United Kingdom

  Co-Author: Lydia Abad-Franch – Sobi, Basel, Switzerland

  Co-Author: Sriya Gunawardena – Sanofi, Bridgewater, NJ, USA

  Co-Author: Karin Fijnvandraat – Emma Kinderziekenhuis/AMC, University of Amsterdam, Netherlands
• 10:15 – 10:30 ICT

  Assessment of global coagulation function under treatment with emicizumab concomitantly with bypassing agents in hemophilia A with inhibitor (UNEBI Study): Multicenter open-label non-randomized trial.
  

  Presenting Author: Kenichi Ogiwara, MD, PhD – Department of Pediatrics, Nara Medical University

  Co-Author: Teruhisa Fujii – Hiroshima University Hospital

  Co-Author: Azusa Nagao, MD, MSc, PhD – Department of Blood Coagulation, Ogikubo Hospital

  Co-Author: Hideyuki Takedani – Department of rehabilitation, NHO Tsuruga Medical Center

  Co-Author: Kumiko Ono, MD, PhD – Division of Science for Joint Reconstruction, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

  Co-Author: Chiai Nagae – Department of Pediatrics, St. Marianna University School of Medicine

  Co-Author: Kagehiro Amano – Department of Laboratory Medicine, Tokyo Medical University

  Co-Author: Atsuki Yamashita – Department of Pediatrics, Yokohama City Seibu Hospital, St. Marianna University School of Medicine

  Co-Author: Rie Shirayama – Department of Pediatrics, University of Occupational and Environmental Health

  Co-Author: Yasuo Horikoshi – Division of Hematology and Oncology, Shizuoka Children’s Hospital

  Co-Author: Satoshi Higasa – Department of Hematology, Hyogo University of Medicine

  Co-Author: Tadashi Matsushita – Nagoya University Hospital, Nagoya, Japan

  Co-Author: Masashi Taki – Department of Pediatrics, St. Marianna University School of Medicine

  Co-Author: Masanori Matsumoto – Department of Hematology and Blood Transfusion Medicine, Nara Medical University Hospital, Kashihara, Japan

  Co-Author: Naoki Ozu – Institute for Clinical and Translational Science, Nara Medical University

  Co-Author: Masato Kasahara – Institute for Clinical and Translational Science, Nara Medical University

  Co-Author: Midori Shima – Thrombosis and Hemostasis Research Center, Nara Medical University

  Co-Author: Keiji Nogami – Nara Medical University, Nara, Japan
• 10:30 – 10:45 ICT

  FVIII In Vitro Bioequivalence of Mim8 Haemostatic Effect by Thrombin Generation Assays
  

  Co-Author: Jacob Lund, PhD – Novo Nordisk A/S, Måløv, Denmark

  Co-Author: Kasper Jensen – ILS Danmark

  Presenting Author: David Lillicrap, MD – Molecular Hemostasis Research Group, Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON, Canada.

  Co-Author: Mirella Ezban – Novo Nordisk